Moors & Cabot Inc. increased its stake in Medtronic PLC (NYSE:MDT – Free Report) by 10.3% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 68,621 shares of the medical technology company’s stock after acquiring an additional 6,388 shares during the quarter. Moors & Cabot Inc.’s holdings in Medtronic were worth $5,921,000 at the end of the most recent reporting period.
Other large investors also recently added to or reduced their stakes in the company. Activest Wealth Management grew its position in shares of Medtronic by 470.9% in the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 259 shares during the period. Team Financial Group LLC purchased a new stake in shares of Medtronic during the third quarter worth about $31,000. Avion Wealth raised its position in shares of Medtronic by 97.8% during the 3rd quarter. Avion Wealth now owns 362 shares of the medical technology company’s stock worth $31,000 after purchasing an additional 179 shares during the last quarter. IAG Wealth Partners LLC acquired a new position in shares of Medtronic during the 2nd quarter worth about $30,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in Medtronic in the 2nd quarter valued at about $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at Medtronic
In other news, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the transaction, the chief executive officer owned 277,866 shares of the company’s stock, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares of the company’s stock, valued at $10,167,936. This represents a 8.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 61,903 shares of company stock worth $5,889,203 in the last quarter. Company insiders own 0.27% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on Medtronic
Medtronic Trading Down 0.0%
MDT opened at $102.84 on Monday. The firm has a market capitalization of $131.54 billion, a price-to-earnings ratio of 25.33, a price-to-earnings-growth ratio of 2.41 and a beta of 0.56. The company’s 50 day simple moving average is $93.72 and its two-hundred day simple moving average is $88.47. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.07 and a quick ratio of 1.54.
Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. During the same period in the prior year, the business earned $1.26 earnings per share. The business’s revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Analysts expect that Medtronic PLC will post 5.98 EPS for the current fiscal year.
Medtronic Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s payout ratio is currently 70.94%.
About Medtronic
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
See Also
- Five stocks we like better than Medtronic
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
